Lumos Pharma, Inc. (LUMO)

Market Cap	37.54M
Revenue (ttm)	2.21M
Net Income (ttm)	-34.92M
Shares Out	8.65M
EPS (ttm)	-4.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	390,873
Open	4.330
Previous Close	4.340
Day's Range	4.330 - 4.340
52-Week Range	1.370 - 4.580
Beta	0.31
Analysts	Buy
Price Target	9.38 (+116.13%)
Earnings Date	Nov 7, 2024

About LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: LUMO
• Website: https://lumos-pharma.com

Financial Performance

In 2023, Lumos Pharma's revenue was $2.05 million, an increase of 34.67% compared to the previous year's $1.52 million. Losses were -$34.03 million, 9.57% more than in 2022.

Analyst Summary

According to 4 analysts, the average rating for LUMO stock is "Buy." The 12-month stock price target is $9.38, which is an increase of 116.13% from the latest price.

Price Target

$9.38

(116.13% upside)

Analyst Consensus: Buy